IQVIA - Pulmonary Clinical Trials

Techno Trends

Techno Trends includes advancements and innovations in pharmaceutical products and technology from around the world. Additionally, you may keep abreast of any recent advancements in the pharmaceutical industry (product information and technological trends).

Salanersen Receives FDA Breakthrough Status for Spinal Muscular Atrophy

Biogen has announced that the US Food and Drug Administration (FDA) has granted Breakthrough Therapy Designation to salanersen, an investigational treatment for spinal muscular atrophy (SMA)....

University of Cincinnati and Johns Hopkins Develop Nanofibre-Based Therapy for Glioblastoma

Researchers from the University of Cincinnati and Johns Hopkins Medicine have developed a promising nanofibre-based drug delivery system designed to improve treatment outcomes for glioblastoma...

Wenda Pharma Secures Breakthrough Therapy Recognition for NHWD-870 HCI

China’s National Medical Products Administration has granted Zhejiang Wenda Pharmaceutical Technology Co., Ltd. Breakthrough Therapy Designation for NHWD-870 HCI....

Terns Pharmaceuticals Secures FDA Breakthrough Therapy Designation for TERN-701 in CML

Terns Pharmaceuticals, Inc. has received Breakthrough Therapy Designation (BTD) from the U.S. Food and Drug Administration for TERN-701, a novel oral allosteric BCR::ABL1 inhibitor....

FORE Biotherapeutics Receives FDA Breakthrough Therapy Designation for Plixorafenib in Brain Cancer

FORE Biotherapeutics has received Breakthrough Therapy Designation from the U.S. Food and Drug Administration (FDA) for its investigational drug plixorafenib, developed for the treatment of adult patients with BRAF V600E-mutated high-grade glioma, a severe form of brain cancer....

Sanofi Secures FDA Breakthrough Therapy Status for Venglustat in Type 3 Gaucher Disease

The US Food and Drug Administration (FDA) has awarded Breakthrough Therapy designation to venglustat, an investigational oral therapy, for the treatment of neurological symptoms in type 3 Gaucher disease (GD3)....

Cleveland Clinic and Kent State Team Use Quantum Computing to Advance Drug Design

Researchers at the Cleveland Clinic, in collaboration with PhD students from Kent State University, have developed a quantum computing-based method that significantly improves drug design...

Shield Therapeutics Receives FDA Approval for ACCRUFeR® in Pediatric Patients

Shield Therapeutics plc has announced that the U.S. Food and Drug Administration (FDA) has approved ACCRUFeR® (ferric maltol) for the treatment of iron deficiency in children aged 10 years and older....

Case Western Reserve Scientists Discover Novel Molecular Target for Parkinson’s Disease

Researchers at Case Western Reserve University have discovered a new biochemical pathway that could lead to treatments targeting the underlying causes of Parkinson’s disease....

Sanofi Received Breakthrough Therapy and Orphan Drug Designations for Rilzabrutinib

Sanofi has announced that Rilzabrutinib has received Breakthrough Therapy designation from the U.S. Food and Drug Administration (FDA) for the treatment of warm autoimmune hemolytic anemia (wAIHA)....